Although the results from persevERA were not statistically significant, they may support using oral SERDs for patients with ER+/HER2– breast cancer.
Mabel Mardones, MD
Advertisement
Articles by Mabel Mardones, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City
3
Sequencing CAR T-Cell Therapy With Bispecifics in Follicular Lymphoma
4
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
5